Adarx Pharmaceuticals raises $446 million in gene therapy IPO
On September 24, 2026, Adarx Pharmaceuticals, a late-stage gene therapy developer, raised $446.3 million in an upsized initial public offering priced at the top of its marketed range.
On September 24, 2026, Adarx Pharmaceuticals, a late-stage gene therapy developer, raised $446.3 million in an upsized initial public offering priced at the top of its marketed range.
No BS check run yet — press ⚖ to extract this story's claims and verify them against independent sources.
Adarx Pharmaceuticals Inc., a late-stage developer of gene therapies, raised $446.3 million in an upsized initial public offering that priced at the top of its marketed range.
ADARx Pharmaceuticals raises $446.3 million in upsized US IPO Reuters